Biocept Laboratories, which develops and markets cancer diagnostic tests, filed on Monday with the SEC to raise up to $23 million in an initial public offering. The San Diego, CA-based company, which was founded in 1997, plans to list on the NASDAQ under the symbol BIOC. Biocept Laboratories initially filed confidentially on August 19, 2013. Aegis Capital is the sole bookrunner on the deal. No pricing terms were disclosed.
